Match Document Document Title
9034377 Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax  
The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage...
9028876 Rate-controlled particles  
Rate-controlled particles, comprising compounds of the formula as a solid dispersion.
9023394 Formulations and methods for the controlled release of active drug substances  
Controlled release formulations and methods for preparing controlled release formulations for delivery of active drug substances are described herein. The formulations described herein may be...
9011912 Extended-release oral dosage forms for poorly soluble amine drugs  
Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling...
9005661 Osmotic pump controlled release tablet and preparation method thereof  
An osmotic pump controlled release tablet and the preparation method thereof are disclosed. The osmotic pump controlled release tablet is composed of tablet core, semipermeable membrane and...
9000046 Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract  
Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol...
8999388 Dual drug dosage forms with improved separation of drugs  
Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and...
8999386 Methylphenidate extended release chewable tablet  
An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated...
8992975 Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia  
The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen...
8980317 Methods and compositions for treating infections comprising a local anesthetic  
The present invention is directed to a drug depot useful for reducing, preventing or treating an infection in a patient in need of such treatment. The drug depot includes a polymer and a...
8980319 Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans  
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form...
8974825 Pharmaceutical compositions for gastrointestinal drug delivery  
A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally...
8975273 Controlled release hydrocodone formulations  
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
8975271 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Controlled release hydrocodone formulations
 
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
8969369 Abuse-resistant controlled-release opioid dosage form  
Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if...
8968778 Threo-DOPS controlled release formulation  
The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an...
8968777 Tranexamic acid formulations with reduced adverse effects  
Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse...
8962569 Compositions comprising spp24 peptide fragments  
Provided herein is tumor suppression composition and methods of making and using the same.
8956662 Phenylephrine pharmaceutical formulations and compositions for colonic absorption  
The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the...
8945620 Solid pharmaceutical compositions containing pregabalin  
A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration....
8945619 Shell-and-core dosage form approaching zero-order drug release  
Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core...
8936809 Method for treating prostate diseases based on local delivery of active substances  
A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs,...
8927014 Misuse preventative, controlled release formulation  
Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a...
8927013 Misuse preventative, controlled release formulation  
Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a...
8920836 Particulates  
A neutral poly(ethyl acrylate, methyl methacrylate) copolymer is employed as a carrier in the manufacture of pharmaceutical formulations containing an active ingredient. The formulations are...
8920834 Misuse preventative, controlled release formulation  
Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a first layer and a second layer. The core comprises a superabsorbent material (for example,...
8920837 Sustained release dosage form  
The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer...
8920821 Pharmaceutical compositions comprising silica microspheres  
The present invention relates to a topical composition which includes a bioactive drug formulated with silica in the form of microspheres, or drugs in a combination with the silica microspheres in...
8920833 Misuse preventative, controlled release formulation  
Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the...
8920835 Paliperidone double-layered osmotic pump controlled release tablet and preparation method thereof  
A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid...
8920838 Delayed-release glucocorticoid treatment of rheumatoid disease  
Provided are methods for the treatment of a rheumatic disease, such as rheumatoid arthritis, ankylosating spondylitis and/or polymyalgia rheumatic, by administering a delayed-release dosage form...
8916195 Sustained release formulation of naltrexone  
A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the...
8911781 Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides  
A novel patient-convenient, cost effective pharmaceutical composition, comprising of thiazolidinediones and biguanide for controlling hyperglycemia manufactured as multilayer tablet and its...
8911780 Multiparticulate L-menthol formulations and related methods  
An L-menthol-containing multiparticulate formulation includes a plurality of individual enteric coated cores containing L-menthol from an at least 80% pure L-menthol source. The enteric coated...
8906412 GABA analog prodrug sustained release oral dosage forms  
Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohex ane acetic acid, are disclosed. The dosage forms are useful for treating...
8901128 Pharmaceutical compositions of ranolazine  
A novel controlled release pharmaceutical dosage form comprising a therapeutically effective amount of ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s),...
8895064 Controlled release and taste masking oral pharmaceutical composition  
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic,...
8895065 Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof  
There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts...
8889186 Modified release compositions comprising tacrolimus  
A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and...
8889185 Modified release compositions comprising tacrolimus  
A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.
8889187 Once a day amoxicillin product comprising immediate and delayed release dosage forms  
An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve...
8883207 Controlled release carvedilol formulation  
A controlled release carvedilol formulation for less frequent, preferably once daily administration is described. The controlled release formulation comprises a therapeutically effective amount of...
8877247 Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist  
Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one...
8877238 Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound  
Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this...
8877241 Morphine controlled release system  
A composition for controlled release of an opioid from a pharmaceutical composition, the method comprises controlling the release of at least one opioid into an aqueous medium by erosion of at...
8871269 Method for the preparation of controlled release formulations  
The methods disclosed herein are of use for the production of controlled release compositions. In particular, the methods provide the contacting of an organic phase containing a bioactive agent...
8871275 Extended release compositions comprising tolterodine  
The present invention deals with extended release pharmaceutical compositions comprising tolterodine, wherein the composition comprises: a) a drug layer comprising tolterodine tartrate,...
8865201 Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant in the manufacture of a medicament for treating female genital disorders  
A hydrophilic matrix is disclosed which comprises: a) at least one polyacrylic acid derivative in preferred amounts of 0.5-40%,b) at least one cellulose ether in preferred amounts of 30-90% andc)...
8865778 Extended release excipient and its use  
A controlled release excipient composition suitable in formulation of a slow or extended release tablet, contains a synergistic mixture of substantially uncross-linked carboxymethyl starch, or...
8858991 Delayed release oral pharmaceutical dosage forms comprising MGBG  
Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time...